Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Permian Research Foundation

Neither a doctor nor a teaching hospital

Research payments

$1,873,011

96 payments

Through program year 2025, Permian Research Foundation is reported as receiving $1,873,011 in research payments, across 96 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $552,067 3
2024 Research $671,153 5
2023 Research $112,358 4
2022 Research $34,356 16
2021 Research $197,471 36
2020 Research $186,395 20
2019 Research $119,211 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $951,162 3 payments
  2. Amgen Inc. $833,817 37 payments
  3. Pfizer Inc. $51,191 19 payments
  4. Esperion Therapeutics, Inc. $18,040 33 payments
  5. Merck Sharp & Dohme Corporation $17,800 3 payments
  6. Dova Pharmaceuticals $1,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $951,162 3 payments
  2. 20170625_Vesalius - CV $189,855 6 payments
  3. Vesalius - CV $165,486 7 payments
  4. 20170625-Vesalius - CV $141,382 2 payments
  5. OCEANa-Outcomes P3 CV $101,924 2 payments
  6. Vesalius-Cv $75,638 3 payments
  7. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) $63,680 1 payment
  8. A Phase 2B Randomized Doubleblind Placebocontrolled Parallel Group Doseranging Study to Assess the Efficacy Safety and Tolerability of Vupanorsen Pf07285557 in Statintreated Participants With Dyslipidemia $51,191 19 payments
  9. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke $44,356 1 payment
  10. Galactic-Hf $24,773 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record